Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
Open accessAbstract
Recurrent vulvovaginal candidiasis is a common disorder which causes significant morbidity among women worldwide, and treatment options are limited. Ibrexafungerp is a novel antifungal agent which was approved in 2021 for treatment of vulvovaginal candidiasis. We present a case of recurrent vulvovaginal candidiasis successfully treated with ibrexafungerp.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Ibrexafungerp was approved in June 2021 by the FDA for the treatment of RVVC in women after menopause.
“In June 2021, ibrexafungerp, a new oral glucan synthase inhibitor, was approved by the FDA for the treatment of RVVC in women after menopause [64].”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [64]
Ibrexafungerp is active against multiple strains of Candida that are resistant to azoles and echinocandins.
“It is active against multiple strains of Candida that are resistant to azoles and echinocandins.”
From Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods (2023) · cites this paper as [64]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Maintenance Fluconazole Therapy for Recurrent Vulvovaginal Candidiasis
Sobel, J. D., Wiesenfeld, H. C., Martens, M., Danna, P., Hooton, T. M., Rompalo, A., Sperling, M., Livengood, C., Horowitz, B., Von Thron, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033114 · Cited by 487 · see citing works
Recurrent vulvovaginal candidiasis
Blostein, F., Levin-Sparenberg, E., Wagner, J., & Foxman, B. (2017) · Annals of Epidemiology · doi:10.1016/j.annepidem.2017.08.010 · Cited by 180 · see citing works
Current treatment options for vulvovaginal candidiasis caused by azole-resistant Candida species
Sobel, J. D., & Sobel, R. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1476490 · Cited by 168 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Treatment of Vulvovaginal Candidiasis—An Overview of Guidelines and the Latest Treatment Methods
Satora, M., Grunwald, A., Zaremba, B., Frankowska, K., Żak, K., Tarkowski, R., & Kułak, K. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12165376 · Cited by 84 · see citing works
- Authors
- Grant, L. M., & Orenstein, R.
- Affiliations
- Mayo Clinic Hospital (US)
- Corresponding author
- Grant, Leah M.
- Venue
- Journal of Investigative Medicine High Impact Case Reports
- Publisher
- SAGE Publications
- Published
- 2022-01
- Volume
- 10
- Pages
- 23247096221123144-23247096221123144
- ISSN
- 2324-7096 (ISSN-L)
- PMC
- PMC9445446
- OpenAlex
- W4294390559
- Cited by
- 7
- References
- 3
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Investigative Medicine High Impact Case Reports (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Life Sciences › Immunology and Microbiology › Microbiology › Reproductive tract infections research
- Health Sciences › Medicine › Epidemiology › Nail Diseases and Treatments
- Keywords
- recurrent vulvovaginal candidiasis, ibrexafungerp, antifungal therapy, Candida, vaginal candidiasis treatment
- MeSH terms
- Antifungal Agents, Candidiasis, Vulvovaginal, Female, Glycosides, Humans, Triterpenes, Fluconazole, Drug Resistance, Fungal
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
